Senzime

Every year, approximately 100 million patients receive neuromuscular blocking drugs as part of anesthesia to facilitate endotracheal intubation and optimize surgical conditions. Recent guidelines recommend that these patients shall be monitored by a quantitative neuromuscular monitor to ensure patient safety, and it is crucial that such monitors are not affected by periodic noise disturbances in the operating room.
 
The new European patent protects the TetraGraph system’s unique noise-cancelling features. The integrated technology optimizes electromyography (EMG)-based signal quality by mitigating disturbances from external, periodic noises that may be present in an operating room. This improvement ensures accurate indications, personalized drug dosing, precise timing of extubation, and more.
 
"Senzime continues to drive strategic innovation with the mission of safeguarding every patient's journey, from anesthesia to recovery. This new patent further strengthens our competitive edge and underscores our leadership in precision-based based patient monitoring in the operating room", commented Philip Siberg, CEO of Senzime
 
The TetraGraph system, a state-of-the-art quantitative neuromuscular monitoring solution, is used by anesthesiologists at hundreds of leading hospitals worldwide. Its proprietary technology enables anesthesiologists to accurately determine the appropriate dose of neuromuscular blocking drugs and their antagonists and to help identify when patients have safely recovered after surgery.
 
Senzime’s comprehensive patent portfolio now includes more than 90 patents related to its products and technologies, reinforcing its commitment to innovation and patient safety.